Latest receivables for MTEM: $800K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2024), MTEM shows a receivables of $800K. That compares with $270K in the prior-year period — up 190.1% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, MTEM's receivables is now $800K (was $270K) — a 190.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Molecular Templates is outperforming or lagging.
Tracking MTEM's receivables over time shows whether Molecular Templates is scaling, shrinking, or reshaping that part of the business. The current reading is $800K That compares with $270K in the prior-year period — up 190.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this receivables page, Stockcircle has Molecular Templates's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $800K) with ownership activity and broader fundamentals.
Molecular Templates's receivables is $800K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.